Literature DB >> 10192993

[Fatal liver necrosis due to allopurinol].

S Pereira1, J Almeida, A O Silva, M Quintas, O Candeias, F Freitas.   

Abstract

Allopurinol hypersensitivity syndrome (AHS) is a severe reaction which is potentially lethal. Exanthematous rash, fever, eosinophilia, and other severe reactions such as toxic epidermal necrolysis, acute vasculitis, and severe hepatic and renal dysfunctions are manifestations of this syndrome. The authors report a case of lethal massive hepatic necrosis due to allopurinol in a patient with the asymptomatic hyperuricemia. They also describe the risk factors most frequently associated with the development of AHS and the strategy for its prevention and consequent reduction of the mortality associated with this syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10192993

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  4 in total

1.  Syncytial giant cell hepatitis in a patient with chronic lymphocytic leukemia.

Authors:  Neil Gupta; Basile Njei
Journal:  J Dig Dis       Date:  2015-11       Impact factor: 2.325

2.  In Vitro and In Vivo Studies on Quercus acuta Thunb. (Fagaceae) Extract: Active Constituents, Serum Uric Acid Suppression, and Xanthine Oxidase Inhibitory Activity.

Authors:  In-Soo Yoon; Dae-Hun Park; Min-Suk Bae; Deuk-Sil Oh; Nan-Hui Kwon; Jung-Eun Kim; Chul-Yung Choi; Seung-Sik Cho
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-22       Impact factor: 2.629

3.  Comparative effects of green and black tea extracts on lowering serum uric acid in hyperuricemic mice.

Authors:  Chuang Zhu; Ling-Ling Tai; Xiao-Chun Wan; Da-Xiang Li; Yong-Qing Zhao; Yan Xu
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

Review 4.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.